SLS Sellas Life Sciences Group Inc
Company Analysis
Latest News
🔴 Sellas Life Sciences is trading 5.8% down in pre-market ahead of Tuesday’s Federal Reserve decision
Sellas Life Sciences is trading 5.8% down now at $10.88, with the decline appearing consistent with broader risk-off trading ahead of Tuesday’s Federal Reserve...
🔴 Sellas Life Sciences is trading 11.05% down today with no clear company-specific catalyst
Sellas Life Sciences is trading 11.05% down now at $12.00 after no clear company-specific catalyst emerged on September 11, 2026. - The latest identified...
🔴 Sellas Life Sciences is trading 4.37% down today with no clear catalyst identified
Sellas Life Sciences is trading 4.37% down now at $12.90 after no clear company-specific catalyst emerged in available September 11, 2026 coverage. - The...
Sellas Life Sciences faces investigation, stock sinks 13% on delayed trial results
Bronstein, Gewirtz & Grossman, LLC is investigating potential legal claims for Sellas Life Sciences investors. The probe follows an August 28, 2026, report...
🟢 Sellas Life Sciences is trading 4.12% up today after three SLS009 abstracts accepted for 2026 AACR
Sellas Life Sciences is trading 4.12% up at $13.77 after announcing on September 2, 2026, that three abstracts evaluating SLS009 in pancreatic cancer models...
🔴 Sellas Life Sciences is trading 4.27% down today as biotech sector falls
Sellas Life Sciences is trading 4.27% down at $12.77, broadly in line with the biotechnology sector, which is down 4.24% during the regular session. - No new...
🔴 Sellas Life Sciences is trading 10.22% down today as REGAL leukemia trial optimism fades
Sellas Life Sciences is trading 10.22% down at $13.65 as investors reverse recent enthusiasm surrounding the REGAL leukemia trial. - No fresh company-specific...
🔴 Sellas Life Sciences is trading 5.5% down today — no fresh company explanation identified
Sellas Life Sciences is trading 5.5% down at $14.38, with no fresh company announcement identified to explain the August 28, 2026 decline. - Recent coverage...
Sellas Life Sciences Rallies, Following ARK Invest’s Cancer Vaccine Endorsement
Sellas Life Sciences shares gained momentum on August 27, 2026. Cathie Wood’s ARK Investment Management highlighted the growth potential of the personalized...
Sellas Stock Jumps 7% on Unverified Leukemia Trial Milestone — But Can Investors Trust a Rumor With This Much at Stake?
Shares of Sellas Life Sciences surged 7.1% to $14.70 on August 27 after an unconfirmed report — originating from a German source — claimed the company's...
🟢 Sellas Life Sciences is trading 10.12% up today on unconfirmed REGAL 80th-event report
Sellas Life Sciences is trading 10.12% up now at $15.12 after renewed attention to an unconfirmed report that the Phase 3 REGAL leukemia trial reached its...
🟢 Sellas Life Sciences is trading 7.1% up today on unconfirmed REGAL 80th-event report
Sellas Life Sciences is trading 7.1% up at $14.70 after renewed attention around an unconfirmed report that the Phase 3 REGAL leukemia trial reached its 80th...
🔴 Sellas Life Sciences is trading 4.19% down today as unconfirmed 80th-event report prompts skepticism
Sellas Life Sciences is trading 4.19% down at $13.50 as investor skepticism grows around an unconfirmed report that the Phase 3 REGAL leukemia trial reached...
🟢 Sellas Life Sciences rises 5.2% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Sellas Life Sciences is trading 10.07% up today ahead of REGAL trial readout
Sellas Life Sciences is trading at $14.75, up 10.07%, as investors anticipate the approaching REGAL trial readout. - No new company-specific announcement was...
🟢 Sellas Life Sciences is trading 5.5% up today on continued REGAL readout interest
Sellas Life Sciences is trading 5.5% up at $14.14, with the gain appearing driven by trading activity and continued interest in the upcoming REGAL readout. -...
🔴 Sellas Life Sciences falls 4.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Goldman Sachs Adds to Its Sellas Bet With a Leukemia Trial Two Deaths From a Verdict — Is the Stock Pricing in Hope or Evidence?
Shares shifted sharply higher as Goldman Sachs disclosed it had quietly added to its position in Sellas Life Sciences just as the company's make-or-break...
🟢 Sellas Life Sciences is trading 8.9% up today after multiple institutions raised their stakes and Phase 3 REGAL trial nears final analysis
- Sellas Life Sciences is trading 8.9% up at $14.27 today, fueled by significant institutional buying and the nearing final analysis of its pivotal Phase 3...
Goldman Sachs boosts Sellas Life Sciences stake, nearing critical leukemia trial results
Goldman Sachs increased its investment in Sellas Life Sciences by acquiring 29,122 additional shares. This purchase raises the firm's total stake by 5.2% to...